Nanobiotherapeutic Based Blood Substitutes

This comprehensive volume will provide the reader with up-to-date information and the latest science on nanobiotherapeutic-based blood substitutes, with one product approved for human use and many more in the pipeline.

Format: Hardback
Length: 1044 pages
Publication date: 13 January 2022
Publisher: World Scientific Publishing Co Pte Ltd

This comprehensive volume offers the reader cutting-edge insights and the most recent advancements in the rapidly evolving field of nanobiotherapeutic-based blood substitutes. Extensively researched, recent developments have made these agents more promising for patient use, with one product already approved for human application and numerous others in the pipeline. These encompass second-generation and even third-generation solutions, the latter featuring enhanced red blood cell functions. Furthermore, the book provides meticulously written and extensively referenced updates on the field's recent history, encompassing pathophysiologic and pharmacologic studies to validate and verify the efficacy and safety of these novel products.

The use of nanobiotherapeutic-based blood substitutes has been extensively studied for several decades. While there have been significant advancements in recent years, making these agents more promising for patient use, there are still many challenges to be addressed. One of the key challenges is the development of safe and effective nanobiotherapeutic-based blood substitutes that can meet the diverse needs of patients. Another challenge is the lack of standardized testing and regulatory guidelines for these agents, which can make it difficult to assess their efficacy and safety.

Despite these challenges, there have been recent updates that make the use of nanobiotherapeutic-based blood substitutes more promising. For example, one product has been approved for human use, and many more are in the pipeline. These products include second-generation and even third-generation solutions, the latter featuring enhanced red blood cell functions. In addition, there are carefully written and referenced updates on the recent history and products in the field, complete with pathophysiologic and pharmacologic studies to validate and verify the efficacy and safety of many of these new products.

One of the key advantages of nanobiotherapeutic-based blood substitutes is their ability to improve blood circulation and reduce the risk of blood-related diseases. These agents can help to improve blood flow, reduce blood viscosity, and improve oxygen delivery to tissues. They can also help to reduce the risk of blood clots, which can be particularly important for patients with cardiovascular diseases.

Another advantage of nanobiotherapeutic-based blood substitutes is their ability to target specific cells and tissues. These agents can be designed to target specific cells or tissues, such as red blood cells or cancer cells, which can help to improve their efficacy and reduce their side effects. This can be particularly important for patients with rare or difficult-to-treat diseases, who may not have other treatment options available.

However, it is important to note that the use of nanobiotherapeutic-based blood substitutes also comes with risks and side effects. For example, these agents can have interactions with other medications or substances, which can cause adverse effects. They can also have potential toxic effects on cells and tissues, which can lead to serious health complications.

To address these risks and side effects, it is important to conduct rigorous clinical trials and follow strict regulatory guidelines. Researchers and manufacturers must carefully evaluate the safety and efficacy of these agents before they are approved for human use. In addition, patients must be carefully monitored and informed about the risks and benefits of these agents before they are administered.

In conclusion, nanobiotherapeutic-based blood substitutes offer a promising solution for patients with blood-related diseases. While there are still many challenges to be addressed, recent advancements have made these agents more promising for patient use. With careful research and development, it is possible to develop safe and effective nanobiotherapeutic-based blood substitutes that can improve the quality of life for patients with blood-related diseases.

Weight: 1300g
Dimension: 162 x 320 x 36 (mm)
ISBN-13: 9789811228681